A phase 1/2 study of retifanlimab (INCMGA00012, Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) combination therapy in patients (Pts) with advanced solid tumors.
INCAGN-02385;INCAGN-02390;Retifanlimab
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: A phase 1/2 study of retifanlimab (INCMGA00012, Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) combination therapy in patients (Pts) with advanced solid tumors. ### Output: INCAGN-02385;INCAGN-02390;Retifanlimab